Literature DB >> 11248649

Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement.

G Schatzl1, A Gsur, G Bernhofer, G Haidinger, S Hinteregger, C Vutuc, A Haitel, M Micksche, M Marberger, S Madersbacher.   

Abstract

OBJECTIVES: To determine whether polymorphisms in 17 hydroxylase (CYP17) and vitamin D receptor (VDR) genes have an association to prostate volume/histology and endocrine patterns in elderly men with lower urinary tract symptoms (LUTS).
METHODS: Elderly men with LUTS underwent the following investigations: International Prostate Symptom Score (IPSS), uroflowmetry, serum prostate-specific antigen (PSA) assessment of prostate volume, and an endocrine study. Polymorphisms of CYP17 (T-->C substitution in the 5' promoter region) and VDR (T1055C) genes were detected by polymerase chain reaction followed by restriction-length polymorphism analysis, using DNA from peripheral white blood cells. Clinical and endocrine parameters and the prostate stroma/epithelial ratio were correlated to CYP17 and VDR genotypes.
RESULTS: A total of 148 (mean +/- SD, 67.0 +/- 9.7 years) patients were analyzed. IPSS (17.8 +/- 7.0), prostate volume (41.9 +/- 17.9 cc), maximum flow rate (10.9 +/- 5.8 mL/s), and PSA (4.7 +/- 4.7 ng/mL) indicate a typical LUTS population. Mean endocrine levels were consistently within age-specific reference values. Neither CYP17 nor VDR gene polymorphisms revealed an association to prostate size, PSA, clinical parameters, and endocrine parameters. Men who had the A1/A1 CYP17 genotype had on average a greater stromal/epithelial ratio than men with the A1/A2 or A2/A2 genotypes, yet after adjusting for multiple testing, this significance disappeared.
CONCLUSIONS: Gene polymorphisms of CYP17 and VDR have no association to prostate volume, clinical parameters, and endocrine parameters in elderly men. The association of CYP17 polymorphism and prostate histology warrants further studies. Assessment of gene polymorphisms might provide new insights into the pathogenesis of benign prostatic hyperplasia and benign prostate enlargement and may hold promise as genetic biomarkers of this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248649     DOI: 10.1016/s0090-4295(00)01004-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?

Authors:  Jeannette M Schenk; Rachel Hunter-Merrill; Yingye Zheng; Ruth Etzioni; Roman Gulati; Catherine Tangen; Ian M Thompson; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2013-06-28       Impact factor: 4.897

2.  Vitamin D Receptor Genetic Polymorphisms and Prostate Cancer Risk: A Meta-analysis of 36 Published Studies.

Authors:  Ming Yin; Sheng Wei; Qingyi Wei
Journal:  Int J Clin Exp Med       Date:  2009-06-15

Review 3.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06

4.  Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis.

Authors:  Kewei Wang; Guosheng Wu; Jinping Li; Wentao Song
Journal:  BMC Cancer       Date:  2016-08-23       Impact factor: 4.430

5.  Updated analysis of vitamin D receptor gene FokI polymorphism and prostate cancer susceptibility.

Authors:  Yuan-Yuan Mi; Yang-Zhi Chen; Jing Chen; Li-Feng Zhang; Li Zuo; Jian-Gang Zou
Journal:  Arch Med Sci       Date:  2016-08-16       Impact factor: 3.318

6.  Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia.

Authors:  Parmeet Kaur Manchanda; Aaron J Kibler; Mei Zhang; Janani Ravi; Hemant K Bid
Journal:  Indian J Urol       Date:  2012-10

7.  Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample.

Authors:  Richard Berges; Andrea Gsur; Elisabeth Feik; Klaus Höfner; Theodor Senge; Ludger Pientka; Andreas Baierl; Martin C Michel; Anton Ponholzer; Stephan Madersbacher
Journal:  World J Urol       Date:  2009-11-17       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.